Thyroid Eye Disease (TED), also known as Graves’ ophthalmopathy, is a serious autoimmune inflammatory condition that targets the orbital tissues, including muscles and fat surrounding the eyes. Closely linked to Graves’ disease and other thyroid dysfunctions, TED often emerges in patients with underlying hyperthyroidism. As the global prevalence of thyroid disorders continues to rise, driven by aging populations, lifestyle factors, and improved diagnostic rates—the pool of patients at risk for TED is expanding significantly. This growing patient base is a key driver fueling demand for targeted TED therapies and shaping market growth trajectories.
New York, USA, Oct. 16, 2025 (GLOBE NEWSWIRE) — Thyroid Eye Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Thyroid Eye Disease (TED), also known as Graves’ ophthalmopathy, is a serious autoimmune inflammatory condition that targets the orbital tissues, including muscles and fat surrounding the eyes. Closely linked to Graves’ disease and other thyroid dysfunctions, TED often emerges in patients with underlying hyperthyroidism. As the global prevalence of thyroid disorders continues to rise, driven by aging populations, lifestyle factors, and improved diagnostic rates—the pool of patients at risk for TED is expanding significantly. This growing patient base is a key driver fueling demand for targeted TED therapies and shaping market growth trajectories.
DelveInsight’s ‘Thyroid Eye Disease Pipeline Insight 2025‘ report provides comprehensive global coverage of pipeline thyroid eye disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the thyroid eye disease pipeline domain.
Key Takeaways from the Thyroid Eye Disease Pipeline Report
- DelveInsight’s thyroid eye disease pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline thyroid eye disease drugs.
- Key thyroid eye disease companies such as Viridian Therapeutics, Inc., Tourmaline Bio, Inc., Hoffmann-La Roche, H. Lundbeck A/S, Alumis, Sling Therapeutics, Inc., Changchun GeneScience Pharmaceutical Co., Ltd., argenx, Minghui Pharmaceutical (Hangzhou) Ltd, Amgen, Crinetics Pharmaceuticals, Ollin Biosciences, Lycia Therapeutics, Inflammasome Therapeutics, and others are evaluating new thyroid eye disease drugs to improve the treatment landscape.
- Promising pipeline thyroid eye disease therapies, such as VRDN-003, TOUR006, Satralizumab, Lu AG22515, lonigutamab, linsitinib, GenSci098, Efgartigimod, MHB018A, AMG 732, CRN12755, OLN102, LCA-0321, K 9, and others, are in different phases of thyroid eye disease clinical trials.
- In September 2025, Viridian Therapeutics, Inc. announced that enrollment is complete in REVEAL-1 and REVEAL-2, Phase III clinical trials for VRDN-003 in patients with active and chronic TED, respectively.
- In August 2025, Alumis announced that the US Food and Drug Administration has granted Fast Track Designation to lonigutamab for the treatment of thyroid eye disease (TED).
- In July 2025, Viridian Therapeutics, Inc. announced that it had entered into an exclusive collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize VRDN-003 in Japan.
- In May 2025, Alumis Inc. announced that it had completed its merger with ACELYRIN, Inc. Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned.
- In April 2025, VelaVigo Bio announced its second out-licensing agreement of a first-in-class asset to Ollin Biosciences, Inc., granting Ollin an exclusive license to develop, manufacture and commercialize VBS-102 globally (excluding Greater China).
- In January 2025, Sling Therapeutics, Inc., announced topline efficacy and safety data from the Phase IIb/III LIDS trial of linsitinib in patients with active, moderate to severe TED.
- In January 2025, ACELYRIN, INC. announced additional Phase II data and the Phase III program design for lonigutamab in Thyroid Eye Disease (TED).
- In October 2024, Minghui Pharmaceutical, Inc. announced positive topline results from its Phase Ib/II clinical trial of MHB018A in patients with active TED.
- In October 2024, H. Lundbeck A/S announced the initiation of the first clinical trial of its CD40L blocker, Lu AG22515, in patients. Lundbeck’s proof-of-concept (PoC) trial will evaluate the efficacy, safety, and tolerability of Lu AG22515 as a potential treatment for Thyroid Eye Disease.
- In August 2024, Changchun GeneScience Pharmaceutical Co., Ltd. announced that GenSci098 Injection has obtained the implied license for clinical trials from the US Food and Drug Administration (FDA). GenSci will conduct clinical trials aimed at treating Thyroid Eye Disease.
Request a sample and discover the recent advances in thyroid eye disease drugs @ Thyroid Eye Disease Pipeline Report
The thyroid eye disease pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage thyroid eye disease drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the thyroid eye disease clinical trial landscape.
Thyroid Eye Disease Overview
Thyroid eye disease, or Graves’ orbitopathy, is a chronic autoimmune inflammatory disorder that affects the tissues surrounding the eyes and is frequently linked with Graves’ disease. It results in symptoms like bulging of the eyes, retraction of the eyelids, and restricted eye movement due to swelling and inflammation of the extraocular muscles and orbital fat. First documented centuries ago, TED continues to be the leading cause of adult proptosis and occurs in about 25–50% of patients with Graves’ disease. Advances in understanding have highlighted the disease’s immune-mediated mechanisms and complex pathophysiology.
Patients with TED typically experience eye bulging, a gritty or dry feeling, redness, irritation, and swollen eyelids. Other symptoms may include double vision, blurred vision, eyelid retraction, and a sensation of deep pressure or pain behind the eyes, particularly during eye movement. These manifestations vary in severity and can significantly affect both eyesight and quality of life. In more severe cases, inflammation can compress the optic nerve, risking vision loss without timely treatment. Patients often report light sensitivity and excessive tearing. The disease usually fluctuates, with active inflammatory periods alternating with stable phases. Inability to fully close the eyes can cause corneal dryness and damage. Thus, early diagnosis and appropriate treatment are crucial to avoiding complications and preserving vision.
TED follows a self-limited progression due to the lack of orbital lymphoid tissue, as described in Rundle’s natural history model. It typically begins with a phase of rapidly worsening symptoms lasting from six months to five years, followed by an active inflammatory phase and eventually an inactive phase after approximately 18 months. Even once stable, fibrotic changes remain, often preventing a full return to normal and frequently requiring surgery during the inactive period. Initiating aggressive immunosuppressive therapy early in the active stage can help minimize lasting tissue damage. The “Cone model” further explains disease evolution: initial circumferential expansion displaces fat, axial elongation results in eye bulging and muscle strain, and eventual cone hypertension causes impaired venous drainage and increased muscle stiffness.
Treatment for TED depends on severity and disease activity. Management begins with smoking cessation and normalization of thyroid function. Mild cases are treated with lubrication, while moderate to severe active cases may require immunosuppressive treatments such as corticosteroids, immunomodulators, or biologics like teprotumumab. Surgical procedures, including orbital decompression and correction of proptosis, strabismus, or eyelid retraction, are reserved for the inactive phase or urgent sight-threatening situations. The overall goal is to control inflammation, prevent complications, and restore both visual function and appearance.
Find out more about thyroid eye disease drugs @ Thyroid Eye Disease Treatment
A snapshot of the Pipeline Thyroid Eye Disease Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| VRDN-003 | Viridian Therapeutics, Inc. | III | IGF type 1 receptor antagonists | Subcutaneous |
| Efgartigimod | argenx | III | Neonatal Fc receptor antagonists | Subcutaneous |
| Satralizumab | Chugai Pharmaceuticals/ Roche | III | Interleukin 6 receptor antagonists | Subcutaneous |
| Linsitinib | Sling Therapeutics, Inc. | II/III | IGF type 1 receptor antagonists; Insulin receptor antagonists; Protein tyrosine kinase inhibitors; Receptor protein-tyrosine kinase antagonists | Oral |
| TOUR006 | Tourmaline Bio, Inc. | II | Interleukin 6 inhibitors | Subcutaneous |
| Lonigutamab | Alumis | II | IGF type 1 receptor antagonists | Subcutaneous |
| Lu AG22515 | Lundbeck A/S | I | CD40 ligand inhibitors | Intravenous |
Learn more about the emerging thyroid eye disease therapies @ Thyroid Eye Disease Clinical Trials
Thyroid Eye Disease Therapeutics Assessment
The thyroid eye disease pipeline report proffers an integral view of the emerging thyroid eye disease therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action.
Scope of the Thyroid Eye Disease Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
- Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
- Therapeutics Assessment By Mechanism of Action: IGF type 1 receptor antagonists, Neonatal Fc receptor antagonists, Interleukin 6 receptor antagonists, Protein tyrosine kinase inhibitors, Receptor protein-tyrosine kinase antagonists, CD40 ligand inhibitors, and others.
- Key Thyroid Eye Disease Companies: Viridian Therapeutics, Inc., Tourmaline Bio, Inc., Hoffmann-La Roche, H. Lundbeck A/S, Alumis, Sling Therapeutics, Inc., Changchun GeneScience Pharmaceutical Co., Ltd., argenx, Minghui Pharmaceutical (Hangzhou) Ltd, Amgen, Crinetics Pharmaceuticals, Ollin Biosciences, Lycia Therapeutics, Inflammasome Therapeutics, and others.
- Key Thyroid Eye Disease Pipeline Therapies: VRDN-003, TOUR006, Satralizumab, Lu AG22515, lonigutamab, linsitinib, GenSci098, Efgartigimod, MHB018A, AMG 732, CRN12755, OLN102, LCA-0321, K 9, and others.
Dive deep into rich insights for new thyroid eye disease treatments, visit @ Thyroid Eye Disease Drugs
Table of Contents
| 1. | Thyroid Eye Disease Pipeline Report Introduction |
| 2. | Thyroid Eye Disease Pipeline Report Executive Summary |
| 3. | Thyroid Eye Disease Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Thyroid Eye Disease Clinical Trial Therapeutics |
| 6. | Thyroid Eye Disease Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Thyroid Eye Disease Pipeline: Late-Stage Products (Phase III) |
| 8. | Thyroid Eye Disease Pipeline: Mid-Stage Products (Phase II) |
| 9. | Thyroid Eye Disease Pipeline: Early-Stage Products (Phase I) |
| 10. | Thyroid Eye Disease Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Thyroid Eye Disease Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Thyroid Eye Disease Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the thyroid eye disease pipeline therapeutics, reach out @ Thyroid Eye Disease Therapeutics
Related Reports
Thyroid Eye Disease Epidemiology Forecast
Thyroid Eye Disease Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted thyroid eye disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Thyroid Eye Disease Market
Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key thyroid eye disease companies, including Binhui Biopharmaceutical Co. Ltd., Hoffmann-La Roche, Adagene Inc., Tempest Therapeutics, Abbisko Therapeutics Co. Ltd., Qilu Pharmaceutical Co Ltd., Mina Alpha Limited, Jiangsu Hengrui Pharmaceutical Co., Ltd., Daiichi Sankyo Inc., Sanofi, Roche Pharma AG, Jennerex Biotherapeutics, Mayo Clinic, Bristol-Myers Squibb, Eli Lilly and Company, among others.
Graves’ Disease Market
Graves’ Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Graves’ disease companies, including Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma and Roivant Sciences, Viridian Therapeutics, Argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, ACELYRIN, among others.
Graves’ Ophthalmopathy Market
Graves’ Ophthalmopathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Graves’ ophthalmopathy companies, including Immunovant Sciences, Novartis, Viridian Therapeutics, among others.
Graves’ Disease Pipeline
Graves’ Disease Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Graves’ disease companies, including Immunovant Sciences GmbH, Sanofi, Biohaven Therapeutics Ltd., Septerna Corporation, among others.
DelveInsight’s Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com